Design, synthesis and biological evaluation of betulinic acid derivatives as potential inhibitors of 3CL-protease of SARS-CoV-2. 2024

Yaowen Liu, and Tianqing Nie, and Jinjun Hou, and Huali Long, and Zijia Zhang, and Min Lei, and Yechun Xu, and Wanying Wu
School of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing 210023, China; Shanghai Research Center for Modernization of Traditional Chinese Medicine, National Engineering Laboratory for TCM Standardization Technology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.

During the coronavirus reproduction process, 3-chymotrypsin-like protease (3CLpro) and papain-like protease (PLpro) are accountable for the fragmentation of two polyprotein precursors (pp1a/pp1ab) into substructural proteins. These two proteins are vital for the replication and transcription of the viral genome. Therefore, 3CLpro is a key protein and target for the design of coronavirus inhibitors. In previous studies, we found that betulinic acid has an inhibitory effect on 3CLpro, with 51.5 % inhibition of 3CLpro at 20 µM. Then, series of betulinic acid derivatives were designed, synthesized, and evaluated for their inhibition activities. The results showed that BA02 and BA05 showed significant inhibitory activity on 3CLpro with inhibitory rates of 78.1 % and 82.5 % at 20 µM, respectively. Further evaluation of these two compounds shows that their IC50 values are 7.22 ± 0.14 μM and 6.40 ± 0.14 μM, respectively.

UI MeSH Term Description Entries
D010447 Peptide Hydrolases Hydrolases that specifically cleave the peptide bonds found in PROTEINS and PEPTIDES. Examples of sub-subclasses for this group include EXOPEPTIDASES and ENDOPEPTIDASES. Peptidase,Peptidases,Peptide Hydrolase,Protease,Proteases,Proteinase,Proteinases,Proteolytic Enzyme,Proteolytic Enzymes,Esteroproteases,Enzyme, Proteolytic,Hydrolase, Peptide
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000086382 COVID-19 A viral disorder generally characterized by high FEVER; COUGH; DYSPNEA; CHILLS; PERSISTENT TREMOR; MUSCLE PAIN; HEADACHE; SORE THROAT; a new loss of taste and/or smell (see AGEUSIA and ANOSMIA) and other symptoms of a VIRAL PNEUMONIA. In severe cases, a myriad of coagulopathy associated symptoms often correlating with COVID-19 severity is seen (e.g., BLOOD COAGULATION; THROMBOSIS; ACUTE RESPIRATORY DISTRESS SYNDROME; SEIZURES; HEART ATTACK; STROKE; multiple CEREBRAL INFARCTIONS; KIDNEY FAILURE; catastrophic ANTIPHOSPHOLIPID ANTIBODY SYNDROME and/or DISSEMINATED INTRAVASCULAR COAGULATION). In younger patients, rare inflammatory syndromes are sometimes associated with COVID-19 (e.g., atypical KAWASAKI SYNDROME; TOXIC SHOCK SYNDROME; pediatric multisystem inflammatory disease; and CYTOKINE STORM SYNDROME). A coronavirus, SARS-CoV-2, in the genus BETACORONAVIRUS is the causative agent. 2019 Novel Coronavirus Disease,2019 Novel Coronavirus Infection,2019-nCoV Disease,2019-nCoV Infection,COVID-19 Pandemic,COVID-19 Pandemics,COVID-19 Virus Disease,COVID-19 Virus Infection,Coronavirus Disease 2019,Coronavirus Disease-19,SARS Coronavirus 2 Infection,SARS-CoV-2 Infection,Severe Acute Respiratory Syndrome Coronavirus 2 Infection,COVID19,2019 nCoV Disease,2019 nCoV Infection,2019-nCoV Diseases,2019-nCoV Infections,COVID 19,COVID 19 Pandemic,COVID 19 Virus Disease,COVID 19 Virus Infection,COVID-19 Virus Diseases,COVID-19 Virus Infections,Coronavirus Disease 19,Disease 2019, Coronavirus,Disease, 2019-nCoV,Disease, COVID-19 Virus,Infection, 2019-nCoV,Infection, COVID-19 Virus,Infection, SARS-CoV-2,Pandemic, COVID-19,SARS CoV 2 Infection,SARS-CoV-2 Infections,Virus Disease, COVID-19,Virus Infection, COVID-19
D000086402 SARS-CoV-2 A species of BETACORONAVIRUS causing atypical respiratory disease (COVID-19) in humans. The organism was first identified in 2019 in Wuhan, China. The natural host is the Chinese intermediate horseshoe bat, RHINOLOPHUS affinis. 2019 Novel Coronavirus,COVID-19 Virus,COVID19 Virus,Coronavirus Disease 2019 Virus,SARS Coronavirus 2,SARS-CoV-2 Virus,Severe Acute Respiratory Syndrome Coronavirus 2,Wuhan Coronavirus,Wuhan Seafood Market Pneumonia Virus,2019-nCoV,2019 Novel Coronaviruses,COVID 19 Virus,COVID-19 Viruses,COVID19 Viruses,Coronavirus 2, SARS,Coronavirus, 2019 Novel,Coronavirus, Wuhan,Novel Coronavirus, 2019,SARS CoV 2 Virus,SARS-CoV-2 Viruses,Virus, COVID-19,Virus, COVID19,Virus, SARS-CoV-2,Viruses, COVID19
D000094062 Betulinic Acid A lupane-type triterpene derivative of betulin which was originally isolated from BETULA or birch tree. It has anti-inflammatory, anti-HIV and antineoplastic activities. 3-Epi-betulinic Acid,3-Hydroxy-lup-20(29)-en-28-oic Acid,3-Hydroxylup-20(29)-en-28-oic Acid,Betulic Acid,3 Epi betulinic Acid
D000998 Antiviral Agents Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral

Related Publications

Yaowen Liu, and Tianqing Nie, and Jinjun Hou, and Huali Long, and Zijia Zhang, and Min Lei, and Yechun Xu, and Wanying Wu
October 2023, Chemical biology & drug design,
Yaowen Liu, and Tianqing Nie, and Jinjun Hou, and Huali Long, and Zijia Zhang, and Min Lei, and Yechun Xu, and Wanying Wu
April 2008, Bioorganic & medicinal chemistry,
Yaowen Liu, and Tianqing Nie, and Jinjun Hou, and Huali Long, and Zijia Zhang, and Min Lei, and Yechun Xu, and Wanying Wu
May 2022, Molecules (Basel, Switzerland),
Yaowen Liu, and Tianqing Nie, and Jinjun Hou, and Huali Long, and Zijia Zhang, and Min Lei, and Yechun Xu, and Wanying Wu
June 2005, Bioorganic & medicinal chemistry letters,
Yaowen Liu, and Tianqing Nie, and Jinjun Hou, and Huali Long, and Zijia Zhang, and Min Lei, and Yechun Xu, and Wanying Wu
July 2013, European journal of medicinal chemistry,
Yaowen Liu, and Tianqing Nie, and Jinjun Hou, and Huali Long, and Zijia Zhang, and Min Lei, and Yechun Xu, and Wanying Wu
June 2010, Bioorganic & medicinal chemistry letters,
Yaowen Liu, and Tianqing Nie, and Jinjun Hou, and Huali Long, and Zijia Zhang, and Min Lei, and Yechun Xu, and Wanying Wu
October 2021, RSC medicinal chemistry,
Yaowen Liu, and Tianqing Nie, and Jinjun Hou, and Huali Long, and Zijia Zhang, and Min Lei, and Yechun Xu, and Wanying Wu
September 2007, Chembiochem : a European journal of chemical biology,
Yaowen Liu, and Tianqing Nie, and Jinjun Hou, and Huali Long, and Zijia Zhang, and Min Lei, and Yechun Xu, and Wanying Wu
December 2023, Bioorganic & medicinal chemistry,
Yaowen Liu, and Tianqing Nie, and Jinjun Hou, and Huali Long, and Zijia Zhang, and Min Lei, and Yechun Xu, and Wanying Wu
June 2017, Bioorganic & medicinal chemistry letters,
Copied contents to your clipboard!